Association between Metabolic Syndrome Risk Factors and Immunohistochemical Profile in Women with Breast Cancer

Background: The association between metabolic syndrome ( MetS) and breast cancer may significantly impact the mortality and incidence of breast cancer. This study aimed to assess the association between MetS risk factors and immunohistochemical ( IHC) profiles in women with breast cancer. Methods: This cross-sectional study used the medical records of 300 breast cancer patients with an average age of 53.11 +/- 12.97 years in the Chemotherapy and Radiation Therapy Clinic of Dr. Anbiai, Tehran, Iran (2020-2021). The cases were divided into five subgroups including luminal A, luminal B ( HER-2(-)), luminal B (HER-2(+)), HER-2 overexpressing, and triple negative. Results: There was no difference in the prognostic indicators between the presence and absence of MetS in women with breast cancer. A higher proportion of luminal A tumors (39.3%), luminal B (HER-2(+)) (25%), triple-negative (17%), luminal B ( HER-2(-)) (10.7%), HER-2 overexpression (8%) was observed in women with MetS than those without MetS. Multivariate logistic regression analysis showed that patients with MetS had a 41% higher chance of developing luminal A than those without MetS, and patients with a BMI >= 30 Kg/m(2) had an 80% higher chance of developing luminal B (HER-2(+)) than those with a BMI<30 Kg/m(2). Moreover, women with a waist circumference higher than 88 cm had a 14 % lower chance of developing Luminal B (HER-2(+)) than those with a waist circumference less than 88 cm. Conclusion: There was no difference in prognostic indicators and IHC profile in patients with and without MetS.